Stock Price



+ 0.56

Day High:

Day Low:


4:00 PM ET on
Aug 28, 2015
Delayed ~20 min. By eSignal.


We are focused on developing and commercializing drugs that treat orphan disease populations.

Investment Thesis

Our lead product candidate, ARIKAYCE, is being developed for patients with severe lung infections.

  • ARIKAYCE is a proprietary inhaled liposomal formulation of the antibiotic amikacin, currently administered intravenously for a range of infections
  • The product is delivered through a specialized nebulizer engineered to deliver amikacin directly to the site of serious lung infections
  • ARIKAYCE is designed for once daily administration

We have multiple near‐term commercial opportunities in orphan lung diseases.

  • In 2014, Insmed filed a Marketing Authorization Application (MAA) with the EMA for ARIKAYCE for the treatment of NTM lung infections as well as Pseudomonas aeruginosa lung infections in cystic fibrosis patients.
  • Insmed is proceeding with a phase 3 study in patients with NTM lung infection. We anticipate having preliminary top-line clinical results from the confirmatory phase 3 study in 2016.

 We have a solid and broad IP portfolio.

  • More than a decade of investment in research and development
  • Potential coverage into 2029

 We are well-capitalized and are building out our infrastructure.

  • $159.2 million in cash (as of December 31, 2014)

View all »   RSSNews Releases

Aug 6, 2015
Insmed Reports Second Quarter 2015 Financial Results and Provides Business Update

Jul 28, 2015
Insmed to Host Second Quarter 2015 Financial Results Conference Call on Thursday, August 6, 2015

View all »Events

Aug 6, 2015
Insmed Second Quarter 2015 Financial Results
Webcast Listen to webcast

Jun 24, 2015
Insmed to participate at the 2015 JMP Securities Life Sciences Conference
Webcast Listen to webcast

Investor Materials

View the latest Insmed Investor Presentation here.

Learn More

Key Clinical Publications

Insmed actively publishes and presents clinical data for its product candidates.

Learn More

Email Alerts

Want to stay up to date on our news, events, and filings?

Set up your email alerts. Learn More

Investor & Media Contacts

Investor Relations
Susan Mesco
Insmed Investor Relations
Phone: (908) 947-4326